Wet AMD

>

Latest News

Image credit: ©gopixa– stock.adobe.com
UC Davis researchers administer Phase 3 ABBV-RGX-314, a gene therapy treatment for wet AMD

September 5th 2023

The experimental gene therapy was administered as a treatment in part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD.

Image credit: ©Araki Illustrations – stock.adobe.com
BREAKING: FDA issues CRL for Outlook Therapeutics’ ONS-5010

August 30th 2023

FDA approves Regeneron’s aflibercept injection 8mg for treatment of DME, DR, wet AMD
FDA approves Regeneron’s aflibercept injection 8mg for treatment of DME, DR, wet AMD

August 19th 2023

Image credit: ©K Davis/peopleimages.com – stock.adobe.com
Adverum Biotechnologies provides an update on Phase 2 LUNA trial evaluating ixoberogene soroparvovec for wet AMD

August 19th 2023

Image credit: ©Victoria Key - Adobe.stock.com
Aflibercept 8 mg data shows durable vision gains at extended dosing intervals for wet AMD

August 14th 2023

Video Series
Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.